Blockchain Registration Transaction Record
Soligenix Reports Q2 2025 Results and Advances Rare Disease Treatments
Soligenix announces Q2 2025 results, showcasing progress in rare disease treatments. Key milestones include Phase 2a results for psoriasis and CTCL therapies. Learn more.

This news is significant for patients with rare diseases and investors in the biopharmaceutical sector. Soligenix's progress in developing treatments for conditions like psoriasis, CTCL, and Behçet’s Disease represents potential new options for patients with limited treatment choices. The company's financial health and pipeline advancements also offer insights into the viability of investing in biotech firms focused on rare diseases, highlighting the intersection of healthcare innovation and investment opportunities.
Blockchain | Details |
---|---|
Contract Address | 0xeA2912a8DA1CD48401b10cB283585874d98098F4 |
Transaction ID | 0x4c7b15130beb2490ed1f20ea2f8efd39121403612bca642d081d517c69229375 |
Account | 0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20 |
Chain | polygon-main |
NewsRamp Digital Fingerprint | gold3ipq-eda7e6f59d30a7bc426402060a03440f |